Lawrence Steinman
Co-Founder & Executive ChairmanDr. Lawrence Steinman, Ph.D., M.D., B.A., also known as Larry, is Advisor of Trethera Corporation from May 2021. Dr. Steinman joined the Trethera Corporation in May 2021. Dr. Steinman is Member of Scientific Advisory Board of EXUMA Biotech Corp. He is Member of Scientific Advisory Board of Ilios Therapeutics, Inc. He serves as a Member of Scientific Advisory Board at Apeximmune Therapeutics Inc. He serves as the Executive Chairman and Co-Founder at Pasithea Therapeutics Corp. and has been its Director since August 2020 and served as its MD. He is a Co-Founder of Neurocrine Biosciences Inc. He serves as Member of Scientific Advisory Board at Trethera Corporation since May 2021. He served as Member of Advisory Board for Medivolve Inc. (formerly known as QuestCap Inc.), since April 2020 until 2021. He is Co Founder of 180 Life Sciences Corp. He served as Executive Co-Chairman of the Board of 180 Life Sciences Corp. since November 6, 2020 until March 07, 2024 and served as its Executive Chairman since March 07, 2024 until May 07, 2024 and had been its Director since November 2020 until August 4, 2025. He served as a Member of Scientific Advisory Board at Coya Therapeutics, Inc. He serves as Chairman of External Scientific Advisory Board & Technical Advisor at Atreca, Inc. since August 22, 2019. He was a Scientific Founder & Executive Chairman of Tolerion Inc. He served as Member of Scientific and Clinical Advisory Board at Equillium, Inc since May 6, 2019 until November 2023. He is the recipient of the Cerami Prize in Translational Research. He holds a number of patents in the areas of immunology, Type 1 diabetes and MS. He co founded Neurocrine Biosciences, Bayhill Therapeutics (now named Tolerion), Nuon Therapeutics, Transparency Life Sciences and Atreca. He was a Director of Centocor Biotech, Inc. from 1989 to 1998. He served as a Member of the advisory Board of BioAtla, Limited Liability Companyfrom April 2016 to July 2020 and served as a scientific advisor to BioAtla, Limited Liability Companyfrom April 2014 to May 2016. He co founded Neurocrine Biosciences Inc. academic. He was Director of Alpha5 Integrin since 2020 until June 2022. He is Chief Scientist of Neuroimmunology and a Member of Neurocrine Biosciences Inc. Founding Board of Scientific and Medical Advisors since September 1992. He has developed two antigen specific therapies, using DNA vaccines, for MS and type 1 diabetes. He served as Member of Scientific Advisory Board at Biocon Limited. He served as an Advisor of Syapse Inc. He served as a Scientific Consultant for Neurocrine Biosciences Inc. He has been an Independent Director of BioAtla, Inc. since July 2020 and also its Lead Independent Director. He serves as Member of Scientific Advisory Board of Applied Therapeutics Inc. He co founded Bayhill Therapeutics, Inc. in 2000. He served as a Scientific and Clinical Advisor of Vaccinex, Inc. He is a Co Founder of Nuon Therapeutics. He served as a Member of the Scientific Advisory Board at KAHR medical Ltd. and Peptimmune, Inc. He served as a Director at Atreca, Inc. from 2010 until August 22, 2019. He serves as a Member of Scientific Advisory Board of Sequenta, Inc. He serves as a Member of Advisory Board at Horizon Pharmaceutical LLC. He serves as Member of The Scientific Advisory Board at Provid Pharmaceuticals, Inc. He serves as a Member of Scientific Advisory Board at Nuon Therapeutics, Inc. Bionure, Inc. and Neurion Pharmaceuticals, Inc. He serves as Member of Clinical Advisory Board at Biocon Limited. He served as a Director of Janssen Biotech, Inc. since 1991. He served as a Director at Bayhill Therapeutics, Inc. since 2001. He served as a Member of the Scientific Advisory Board at Roche Biosciences, Inc. from 1998 to 2002. He served as a Director of Garnet Biotherapeutics, Inc. (formerly, Neuronyx, Inc). He served as a Director of Neurocrine Biosciences Inc. since 2001. He served as a Member of Scientific Advisory Board at Centocor, Inc. from 1990 to 1999. He was Director of Tolerion, Inc. from 2013 to 2021. He is Chair of the Stanford University Program in Immunology. He returned to Stanford University Hospital as a resident in pediatric and adult neurology and then joined the faculty at Stanford in 1980. Since 1980, he has been the faculty at Stanford University, where he is Professor of Neurological Sciences, Neurology and Pediatrics. He was senior author on the seminal 1992 Nature article that reported the key role of a particular integrin in brain inflammation. This research led to the development of the drug Tysabri, which is used to treat patients with MS and Crohn disease. He was honored with the Weir Mitchell Award of the American Academy of Neurology and the Senator Jacob Javits Neuroscience Investigators Award from the U. S. Congress and the National Institutes of Health (NIH) as well as The. Dr. Friedrich Sasse Award for Outstanding Contributions in Immunology from the Free University of Berlin. He is a Board Certified with the American Board of Psychiatry and Neurology. He holds 7 US patents for diagnosis and therapy of autoimmune disease and is the recipient of the Senator Jacob Javits Award from the U. S. Congress and National Institutes of Health. He is a Member of the Institute of Medicine of the National Academy of Sciences. He was the NIH Fellow at Harvard Medical School from 1970 to 1971. He received his M. D. from Harvard University School of Medicine in 1973. He holds an AB in physics from Dartmouth College in 1968. He completed his residency training in Neurology at Stanford University. He served as a Member of RMS Clinical Advisory Board at Receptos, Inc. He served as a Member of the Clinical Advisory Board at Receptos, Inc. He was Director of Neurocine Biosciences from 1997 to 2005. He is the George A. Zimmermann Endowed Chair in the Neurology Department at Stanford University and previously served as the Chair of the Interdepartmental Program in Immunology at Stanford University Medical School from 2003 to 2011. He is a Member of the National Academy of Medicine and the National Academy of Sciences. He also founded the Steinman Laboratory at Stanford University, which is dedicated to understanding the pathogenesis of autoimmune diseases, particularly multiple sclerosis and neuromyelitis optica. He received the Frederic Sasse Award from the Free University of Berlin in 1994, the Sen. Jacob Javits Award from the U. S. Congress in 1988 and 2002, the John Dystel Prize in 2004 from the National MS Society in the U. S. the Charcot Prize for Lifetime Achievement in Multiple Sclerosis Research in 2011 from the International Federation of MS Societies and the Anthony Cerami Award in Translational Medicine by the Feinstein Institute of Molecular Medicine in 2015. He also received an honorary Ph.D. at the Hasselt University in 2008 and from the University of Buenos Aires in 2022. He also completed a fellowship in chemical immunology at the Weizmann Institute (1974 1977) and was an int
Positions
- Company NamePasithea Therapeutics Corp.Stock CodeKTTAPositionCo-Founder & Executive ChairmanColleagues
- Company NameBioAtla, Inc.Stock CodeBCABPositionLead Independent DirectorColleagues
- JMJay M. ShortCo-Founder, CEO & Chairman
- CJChristian J. VasquezCFO & Corporate Secretary
- SMSusie MelodySenior Vice President of Human Resources
- CCCathy ChangSenior Vice President of Research & Development
- GFGerhard FreySenior Vice President of Technology Development
- MAMary Ann GrayIndependent Director
- SSSylvia S. McBrinnIndependent Director
- JPJames Patrick AllisonAdvisor
